retatrutide clinical trial results weight loss VisualAbstract: reduces body by 17.5% in patients with obesity What Is Retatrutide?: The New

The pharmacokinetics of LY3437943 (retatrutide) support once-weekly administration due to an elimination half-life of approximately 6 days. Jastreboff AM et al., Nature Medicine, 2023 This extended half-life is made possible by attaching a fatty acid chain to the peptide, allowing it to bind to albumin a common protein in your blood that acts like a slow-release carrier

(These tasks can be complicated by GLP-1 medications, which commonly cause nausea, vomiting and reduced appetite.) Restarting GLP-1 medications may be an option, Buie said, for the following reasons: Weight loss eventually plateaus or stalls after bariatric surgery Additional bariatric surgery isn't possible (such as converting a sleeve gastrectomy to a duodenal switch) Weight regain has occurred years after having bariatric surgery

doi:10.1001/jamaophthalmol.2024.2296 Lisco G, De Tullio A, Disoteo O, et al

Study approval